Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib Paediatric NF1 Japan Study
NCT04495127Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability in terms of adverse events. Started Aug 2020; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT04495127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495127.